Thu, Jul 24, 2014, 7:18 AM EDT - U.S. Markets open in 2 hrs 12 mins

Recent

% | $
Click the to save as a favorite.

Albany Molecular Research Inc. Message Board

  • chemmavin chemmavin May 13, 2005 12:39 PM Flag

    for all you longs

    FYI, here's a little insight, albeit an old article, into the short seller's tactics:

    http://www.otcjournal.com/geist5.html

    Long and strong!!!

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • maybe so but there is a helluva lot of insider
      buying betting against you. just a thought...
      just a thought...mw

    • <<<As for �busting� through $12 I think you may be right short term, but realistically this is a great short. Looking to increase my short position after a few more patents fall.>>>

      You will then be waiting a few years before increasing your short imho.

    • Are you related to the psychotropic Amrithebest???? �Patents for Allegra are VERY solid also imho.� So �SOLID� that the first four have already been thrown out. �The outcome will result exactly like LLY's recent long awaited patent challenge imho� OMG what are you thinking??? Lilly is an American company that fought a different patent lawsuit in Indianapolis which just happens to be their home town!!!! This French company is defending and losing it�s patents in New York city!!!! As for �busting� through $12 I think you may be right short term, but realistically this is a great short. Looking to increase my short position after a few more patents fall.

    • sorry, your're a 100% correct, it's a mistake, I meant Barr pharmaceuticals, not sanofi-aventis...

    • <<<if sanofi-aventis goes after this patent, it is because they think that they found a flaw...>>>

      It sounds as though you believe Sanofi-Aventis is challenging AMRI's Allegra manufacture related patent and royalty stream. I was under the impression AMRI's real worry was that the generic companies are challenging Sanofi-Aventis patent for the exclusive sale of Allegra and if they succeed then AMRI's patent for the superior manufacture of the drug might be in jeopordy too. As long as Sanofi-Aventis holds control of their exclusive sales of Allegra then AMRI will keep receiving their royalties.

    • yes and no, most drug patents are challenged by generic companies because it is their line of business, hence they give a shot at anything... big big pharmas only attack if their lawyers think that they have a good chance of winning, as a lot of money will have to be spent in this process...if sanofi-aventis goes after this patent, it is because they think that they found a flaw... and it is always possible, who knows???

    • We would have laughed harder if you would have said what if AMRI wins it�s process patent!!!!!!! Typical response from the mindset of Nano-management (do you work at AMRI?)!!!!! As we all know the lawsuits are a delaying tactic aren�t they!!!!!!

    • <<<Sanofi-Aventis lawyers also will remain busy because several companies are mounting a patent fight over Allegra.>>>

      Are there any major drugs on the market that don't have any patent challenges? The outcome will result exactly like LLY's recent long awaited patent challenge imho. Patents for Allegra are VERY solid also imho.
      AMRI will be busting through $12 whithin a week.

    • ........and if Sanofi-Aventis wins??????

    • Sanofi-Aventis lawyers also will remain busy because several companies are mounting a patent fight over Allegra. No trial date has been set, says Anderson. If Sanofi-Aventis loses, he figures generic challengers might reach the market in mid-2006.

    • View More Messages
 
AMRI
20.24-0.15(-0.74%)Jul 23 4:00 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
Facebook, Inc.
NasdaqGSWed, Jul 23, 2014 4:00 PM EDT
Gilead Sciences Inc.
NasdaqGSWed, Jul 23, 2014 3:59 PM EDT